Work

Abstract OT2-24-03: Phase II study of a PARP inhibitor in metastatic breast cancer with somaticBRCA1/2mutations identified by cell-free DNA: Genotyping based clinical trial

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs21-ot2-24-03

Authors: Neelima Vidula, Erica Blouch, Erin Basile, Nathan Royce Ruffle-Deignan, Nora Horick, Senthil Damodaran, Alvaro Moreno Aspitia, Manali Bhave, Ami Shah, Minetta C. Liu, Joseph Sparano, Harry Ostrer, Hope Rugo, Leif W. Ellisen, Aditya Bardia

Institutions: Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Mayo Clinic in Florida, Emory University, Northwestern University, Mayo Clinic, Albert Einstein College of Medicine, University of California, San Francisco

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4220958205

Cites:

Cited by: 1

Related to: 10